DE602004022702D1 - Verfahren und kit zur abschätzung der nebenwirkung durch eine paclitaxel-therapie - Google Patents

Verfahren und kit zur abschätzung der nebenwirkung durch eine paclitaxel-therapie

Info

Publication number
DE602004022702D1
DE602004022702D1 DE602004022702T DE602004022702T DE602004022702D1 DE 602004022702 D1 DE602004022702 D1 DE 602004022702D1 DE 602004022702 T DE602004022702 T DE 602004022702T DE 602004022702 T DE602004022702 T DE 602004022702T DE 602004022702 D1 DE602004022702 D1 DE 602004022702D1
Authority
DE
Germany
Prior art keywords
ims
seq
kit
assessing
side effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004022702T
Other languages
English (en)
Inventor
Yoshio Miki
Masaaki Matsuura
Minoru Isomura
Satoshi Miyata
Masataka Yoshimoto
Tetsuo Noda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japanese Foundation for Cancer Research
Original Assignee
Japanese Foundation for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japanese Foundation for Cancer Research filed Critical Japanese Foundation for Cancer Research
Publication of DE602004022702D1 publication Critical patent/DE602004022702D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE602004022702T 2003-11-05 2004-11-05 Verfahren und kit zur abschätzung der nebenwirkung durch eine paclitaxel-therapie Active DE602004022702D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003375369 2003-11-05
PCT/JP2004/016805 WO2005045029A1 (ja) 2003-11-05 2004-11-05 パクリタキセル療法による副作用を予測する方法およびキット

Publications (1)

Publication Number Publication Date
DE602004022702D1 true DE602004022702D1 (de) 2009-10-01

Family

ID=34567070

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022702T Active DE602004022702D1 (de) 2003-11-05 2004-11-05 Verfahren und kit zur abschätzung der nebenwirkung durch eine paclitaxel-therapie

Country Status (8)

Country Link
US (1) US20070238098A1 (de)
EP (1) EP1688492B1 (de)
JP (1) JP4549297B2 (de)
KR (1) KR20070003777A (de)
CN (1) CN1871349B (de)
AT (1) ATE440153T1 (de)
DE (1) DE602004022702D1 (de)
WO (1) WO2005045029A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260603A1 (en) 2002-12-31 2005-11-24 Mmi Genomics, Inc. Compositions for inferring bovine traits

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528260B1 (en) * 1999-03-25 2003-03-04 Genset, S.A. Biallelic markers related to genes involved in drug metabolism
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
ATE475707T1 (de) * 2001-06-01 2010-08-15 Pgxhealth Llc Polymorphismen im menschlichen gen für cytochrom p450 polypeptid cyp2c8 und deren verwendung in diagnose undtherapie
JP2003093068A (ja) * 2001-09-25 2003-04-02 Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho 代謝酵素ｃｙｐ２ｃ８の多型を利用した、薬物代謝の検査方法および検査薬並びに薬物代謝を改善する化合物のスクリーニング方法
JP2005524388A (ja) * 2001-11-28 2005-08-18 ディーエヌエープリント ジェノミクス インコーポレーティッド パクリタキセル応答性予測の一塩基多型及びそれらの組合せ

Also Published As

Publication number Publication date
CN1871349A (zh) 2006-11-29
US20070238098A1 (en) 2007-10-11
KR20070003777A (ko) 2007-01-05
JPWO2005045029A1 (ja) 2007-05-17
EP1688492A1 (de) 2006-08-09
CN1871349B (zh) 2011-04-06
EP1688492B1 (de) 2009-08-19
JP4549297B2 (ja) 2010-09-22
ATE440153T1 (de) 2009-09-15
WO2005045029A1 (ja) 2005-05-19
EP1688492A4 (de) 2006-12-20

Similar Documents

Publication Publication Date Title
DK1159453T3 (da) Fremgangsmåde til direkte nukleinsyresekventering
WO2004052175A3 (en) Methods for rapid identification of pathogens in humans and animals
WO2004060278A3 (en) Methods for rapid identification of pathogens in humans and animals
SG134283A1 (en) Biomarkers for liver fibrotic injury
ATE348881T1 (de) Thermostabiles taq polymerase fragment
WO2004113570A3 (en) Genotype test for dogs
WO2003046203A3 (en) Genetic markers associated with desirable and undesirable traits in horses, methods of identifying and using such markers
ATE469162T1 (de) Verfahren und zusammensetzungen zur identifizierung und charakterisierung von hepatitis c
DE602004022702D1 (de) Verfahren und kit zur abschätzung der nebenwirkung durch eine paclitaxel-therapie
WO2003064600A3 (en) The il-1 gene cluster and associated inflammatory polymorphisms and haplotypes
DE60324819D1 (de) Verfahren zur amplifikation von nukleinsäure, kit zur amplifikation von nukleinsäure, verfahren zum nachweis von einzelnukleotid-polymorphismus und reagentienkit zum nachweis von einzelnukleotid-polymorphismus
ATE432996T1 (de) Verfahren zur bestimmung des bodenzustands
ATE544852T1 (de) Verfahren zur beurteilung der gefahr arzneimittelinduzierter granulozytopenie
WO2003014879A3 (en) System and method for identifying a genetic risk factor for a disease or pathology
DE60212930D1 (de) Detektionsmethode für Zielmoleküle, Reagenz sowie Verfahren zur Detektion von SNPs in DNA Nukleotidsequenzen
ATE488603T1 (de) Suszeptibilitätsgen für die alzheimersche krankheit
WO2004063324A3 (en) Canine gene microarrays
DE60212861D1 (de) Verfahren zur Diagnose von Fettsucht
SE0103423D0 (sv) Polymorphism
DE602004014135D1 (de) Verfahren und zusammensetzungen zur vorhersage der irinotecantoxizität
HUP0203080A2 (hu) A PRV-1 gén és felhasználása
DE60304518D1 (de) Genetisches Verfahren zur Vorhersage des Glaukomarisikos
ATE407145T1 (de) Analyse und verwendung von par 1 polymorphismen zur risikoabschätzung für kardiovaskuläre erkrankungen
ATE435924T1 (de) Verfahren zur identifizierung der milchproduktionsqualitäten in tieren durch analyse der pit-1 und kappa-kasein genpolymorphismus
WO2007107785A3 (en) Genetic markers in the alpha-1-antichymotrypsin (act) gene

Legal Events

Date Code Title Description
8364 No opposition during term of opposition